Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients.

@article{LoewFriedrich1991TherapyWR,
  title={Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients.},
  author={Iris Loew-Friedrich and Peter Gruetzmacher and Winfried Maerz and Marion Bergmann and Wilhelm Schoeppe},
  journal={American journal of nephrology},
  year={1991},
  volume={11 1},
  pages={54-60}
}
The substitution of recombinant human erythropoietin (rhEPO) in chronic hemodialysis patients is often associated with the development of severe hypertension. In the present study, a systematical echocardiographic analysis was performed in 25 patients on maintenance hemodialysis during rhEPO therapy for at least 4 months. Referred to the total group… CONTINUE READING